How to stop a cancer scare with this free eBook

The American Cancer Society says it is urging Americans to stay away from a new drug for cancer patients.

The group is warning people to avoid the drug, Natalizumab, due to the risk of side effects including liver damage.

The drug is marketed by Bristol-Myers Squibb, which was acquired by AstraZeneca in 2016.

The American Academy of Family Physicians has warned that Natalizec can lead to a number of side-effects, including liver cancer.

But the AMA says Natalizaumab “has proven effective in reducing mortality from cancer.”

Natalismumab is an oral anti-inflammatory drug.

According to the Mayo Clinic, it can help prevent or treat arthritis, rheumatoid arthritis, cancer, diabetes, and chronic obstructive pulmonary disease.

Natalisiumab has been tested on animals, but its safety has not been proven in humans.

Natsalizumabs effectiveness was studied by a group at Boston University.

They reported a statistically significant decrease in mortality from prostate cancer in a small trial involving 832 patients.

There was no significant difference in the overall mortality rate, according to the researchers.

They also found that Natsalidizumacin showed a statistically significantly greater survival in prostate cancer patients who were receiving Natalizer.

This could mean that the drug could be more effective in patients with other types of cancers.

Nada.

That’s not the whole story though.

A study published last year by the journal Annals of Internal Medicine showed that the drugs efficacy in other types and cancers is still unknown.

“The drug has not yet been evaluated in humans, and the potential of Natalisumab to affect breast cancer is unclear,” the study authors wrote.

They suggest that Nataicizumabo “may be better tolerated in some patients with a higher degree of liver disease.”

But they also noted that the benefits of Natsals effectiveness may not be realized.

In a commentary, lead author of the study Dr. John A. Raffaelli said, “We know that Naxalumab can be very effective in curbing some cancers, but we do not know if it can have an impact on other cancers.

The study of Nataicsumab was done in mice and has not established whether it can work in humans.”

In a statement, Bristol-MYERS, which acquired Natalizes, said, Natsaliizumabl is the latest in a line of Naturals and is approved for use in humans by the Food and Drug Administration.

The company said that it has a history of delivering the best-quality drugs to patients who require them, and has provided ongoing research to better understand its effectiveness.

“We continue to support the American Cancer Association and the FDA, which have been critical of our drug development,” the statement said.

A version of this story was originally published by Business Insider.